? SHARED RESOURCES MANAGEMENT The Ohio State University Comprehensive Cancer Center (OSUCCC) manages and supports 16 CCSG-funded Shared Resources (SRs) and is proposing two developing shared resources in this application. The goals of the OSUCCC SRs are to support OSUCCC members by providing specialized technologies, services, and expertise that maximize quality and speed of service, while maintaining cost-effectiveness and quality control. The SRs support all five Research Programs and are managed by faculty from seven different colleges and Nationwide Children?s Hospital. Most of the SRs are centrally located and in close proximity to OSUCCC members.
The Specific Aims for Shared Resource Management are to: 1) evaluate for need, and establish new specialized technologies, services and expertise that enhance scientific interaction and productivity; 2) ensure that the SRs provide cost-effective, reliable, and quality-controlled technologies, services and expertise; 3) support SRs through budget planning, laboratory management systems, and sustainability; and 4) establish policies for SR access and use. The OSUCCC directly manages 13 of the 16 SRs, and the others are jointly managed as institutional SRs that follow NCI policies. Reporting to the OSUCCC Director, the SRs are led by Sharyn Baker, PharmD, PhD, Associate Director for Shared Resources. Dr. Baker works with Heather Hampel MS, LGC, Associate Director for Biospecimen Research for integration of biospecimen services with the SRs. Dr. Baker leads the Shared Resource Team Leader (SRTL) committee that oversees SR management and implementation of the scientific vision. The SRTL monitors quality and user satisfaction through user surveys and user committees. SR development and evaluation is provided to Dr. Baker from the Associate Directors Committee, Program Leaders, and the External Scientific Advisory Board. Shared Resource Management operations include ensuring compliance with OSUCCC policies (prioritization of use and access, budgets, billing, and quality control) and compliance with OSU Office of Research policies and the federal Uniform Guidance. For the evaluation of new instrumentation and services, Dr. Baker manages the Intramural Research Program (IRP) that provides external peer review of SR applications, evaluating scientific merit and planned usage ($3.4M awarded this grant cycle. Overall support to the SRs over the last grant cycle has been $18M, allowing for all of the SRs to have been enhanced and offer new services. Future plans for each SR are accounting for planned increased usage due to the OSUCCC strategic research priorities and planned recruitment. The OSUCCC provides over $9M in overall support of the SRs annually, The OSUCCC is requesting a total of $1,971,340 in CCSG funding, 8.9% of the total support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090000
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280

Showing the most recent 10 out of 2602 publications